Suthee Rapisuwon, MD, medical oncologist, MedStar Health, discusses clinical trial barriers for patients with mucosal melanoma in the United States.
Video Reports
Jessica C. Hassel, MD, on Uveal Melanoma: Comparing Tebentafusp With Standard Therapies
Jessica C. Hassel, MD, of University Hospital Heidelberg, discusses phase III results of a study that compared tebentafusp, a bispecific fusion protein, with investigator’s choice in patients with metastatic uveal melanoma.
Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma
Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, discusses the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF-mutated melanoma.
Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments
Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.